KalVista Pharmaceuticals (NASDAQ:KALV) Posts Earnings Results, Misses Expectations By $0.03 EPS

KalVista Pharmaceuticals (NASDAQ:KALV) released its quarterly earnings results on Wednesday. The specialty pharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.03), Zacks reports.

KalVista Pharmaceuticals Trading Up 1.2 %

Shares of NASDAQ:KALV traded up $0.15 during mid-day trading on Wednesday, hitting $12.58. 118,944 shares of the company traded hands, compared to its average volume of 418,056. The stock has a 50-day moving average price of $9.53 and a two-hundred day moving average price of $10.27. KalVista Pharmaceuticals has a 12-month low of $7.30 and a 12-month high of $15.50. The stock has a market cap of $621.68 million, a P/E ratio of -3.46 and a beta of 0.76.

Insider Activity at KalVista Pharmaceuticals

In other news, major shareholder Venrock Healthcare Capital Par acquired 14,562 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was purchased at an average price of $9.22 per share, for a total transaction of $134,261.64. Following the purchase, the insider now owns 5,012,796 shares in the company, valued at approximately $46,217,979.12. This represents a 0.29 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Benjamin L. Palleiko sold 6,669 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $11.97, for a total transaction of $79,827.93. Following the transaction, the chief executive officer now directly owns 287,811 shares in the company, valued at approximately $3,445,097.67. This represents a 2.26 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders purchased 236,055 shares of company stock valued at $2,162,146 and sold 17,292 shares valued at $184,625. 10.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

KALV has been the topic of several research reports. Bank of America began coverage on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price target on the stock. JMP Securities started coverage on KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an “outperform” rating and a $19.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. Citizens Jmp raised KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st. Finally, TD Cowen assumed coverage on KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price objective for the company. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, KalVista Pharmaceuticals has a consensus rating of “Buy” and an average price target of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).